Skip to content

EVOKE PHARMA, INC.: 10-Q filed 2024-11-07

What EVOKE PHARMA, INC. reported in its quarterly report filed 2024-11-07 (fiscal Q3 2024): 26 published measures, 88 facts as tagged in accession 0000950170-24-123338.

This filing

Form
10-Q (quarterly report)
Filed
2024-11-07
Fiscal period
fiscal Q3 2024
Accession
0000950170-24-123338 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All EVOKE PHARMA, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2024-09-3014,153,571USD
At 2023-12-317,068,546USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2024-09-309,766,435USD
At 2023-12-319,648,083USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2024-09-304,387,136USD
At 2024-06-302,664,958USD
At 2024-05-143,500,000USD
At 2024-03-313,497,169USD
At 2023-12-31-2,579,537USD
At 2023-09-30-873,775USD
At 2023-06-30538,374USD
At 2023-03-312,126,151USD
At 2022-12-314,084,649USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2024-09-3011,339,032USD
At 2023-12-314,739,426USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2024-07-01 to 2024-09-30-1,312,390USD92
2024-01-01 to 2024-09-30-4,159,428USD274
2024-04-01 to 2024-06-30-1,267,218USD91
2024-01-01 to 2024-03-31-1,579,820USD91
2023-07-01 to 2023-09-30-1,693,907USD92
2023-01-01 to 2023-09-30-5,804,894USD273
2023-04-01 to 2023-06-30-1,867,917USD91
2023-01-01 to 2023-03-31-2,243,070USD90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2024-01-01 to 2024-09-30-4,218,700USD274
2023-01-01 to 2023-09-30-3,878,873USD273

Contract revenue excluding tax

Revenue from customer contracts excluding assessed taxes under this specific taxonomy concept. It is not automatically comparable to older revenue tags.

PeriodValueUnitDays
2024-07-01 to 2024-09-302,654,186USD92
2024-01-01 to 2024-09-306,941,042USD274
2023-07-01 to 2023-09-301,562,860USD92
2023-01-01 to 2023-09-303,504,636USD273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2024-01-01 to 2024-09-3010,818,306USD274

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2024-09-30-127,598,866USD
At 2023-12-31-123,439,438USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2024-07-01 to 2024-09-301,399,882shares92
2024-01-01 to 2024-09-301,381,703shares274
2023-07-01 to 2023-09-30278,558shares92
2023-01-01 to 2023-09-30278,558shares273

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2024-07-01 to 2024-09-301,399,882shares92
2024-01-01 to 2024-09-301,381,703shares274
2023-07-01 to 2023-09-30278,558shares92
2023-01-01 to 2023-09-30278,558shares273

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2024-07-01 to 2024-09-30-0.94USD/shares92
2024-01-01 to 2024-09-30-3.01USD/shares274
2023-07-01 to 2023-09-30-6.08USD/shares92
2023-01-01 to 2023-09-30-20.84USD/shares273

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2024-07-01 to 2024-09-30-0.94USD/shares92
2024-01-01 to 2024-09-30-3.01USD/shares274
2023-07-01 to 2023-09-30-6.08USD/shares92
2023-01-01 to 2023-09-30-20.84USD/shares273

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2024-07-01 to 2024-09-30131,587USD92
2024-01-01 to 2024-09-30512,194USD274
2023-07-01 to 2023-09-30281,758USD92
2023-01-01 to 2023-09-30846,470USD273

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2024-07-01 to 2024-09-30-1,285,657USD92
2024-01-01 to 2024-09-30-4,010,439USD274
2023-07-01 to 2023-09-30-1,603,437USD92
2023-01-01 to 2023-09-30-5,542,973USD273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2024-09-3014,038,083USD
At 2023-12-316,826,909USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2024-07-01 to 2024-09-30126,027USD92
2024-01-01 to 2024-09-30375,342USD274
2023-07-01 to 2023-09-30126,028USD92
2023-01-01 to 2023-09-30373,973USD273

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2024-09-309,766,435USD
At 2023-12-319,648,083USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2024-07-01 to 2024-09-303,939,843USD92
2024-01-01 to 2024-09-3010,951,481USD274
2023-07-01 to 2023-09-303,166,297USD92
2023-01-01 to 2023-09-309,047,609USD273

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2024-09-30493,408USD
At 2023-12-31481,840USD

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

PeriodValueUnitDays
2024-07-01 to 2024-09-303,824,142USD92
2024-01-01 to 2024-09-3010,697,128USD274
2023-07-01 to 2023-09-303,131,389USD92
2023-01-01 to 2023-09-308,745,407USD273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2024-09-30894,843shares
At 2023-12-31278,558shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2024-09-3011,339,032USD
At 2023-12-314,739,426USD
At 2023-09-305,964,826USD
At 2022-12-319,843,699USD

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2024-07-01 to 2024-09-30-26,733USD92
2024-01-01 to 2024-09-30-148,989USD274
2023-07-01 to 2023-09-30-90,470USD92
2023-01-01 to 2023-09-30-261,921USD273

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2024-01-01 to 2024-09-301,349,447USD274
2023-01-01 to 2023-09-30609,072USD273

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2024-01-01 to 2024-09-3011,568USD274
2023-01-01 to 2023-09-30215,547USD273

Inspect the source

Entity
EVOKE PHARMA, INC. / CIK 0001403708
Captured
2026-09-21T17:19:23.305Z
SEC response SHA-256
1d2ea0edbbb48066d62d49983dacdd25cf55cdf81e3ee5a742e26303a1f7d06e

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001403708.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))